Source: International Congress 2015 – A morphological view of chest pathology
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Aleksandar Ivkovic (Nis, Republic of Serbia), Aleksandar Ivkovic, Tamara Milosavljevic, Stevan Ivkovic. Interstitial lung disease caused by designer drugs. Eur Respir J 2015; 46: Suppl. 59, 769

Member's Comments

No comment yet.

Related content which might interest you: Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Variation in mortality from interstitial lung disease by diagnosis Source: International Congress 2015 – IIPs: orphan Year: 2015 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Chronic interstitial lung disease in children Source: International Congress 2017 – Paediatric year in review: update on paediatric pulmonology Year: 2017 Chronic interstitial lung disease in children Source: Eur Respir Rev, 27 (147) 170100; 10.1183/16000617.0100-2017 Year: 2018 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Morality predictors in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Acute exacerbations of interstitial lung disease Source: Eur Respir Monogr 2016; 74: 117-131 Year: 2016 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Chronic hypersensitivity pneumonitis: Is the interstitial pneumonias disease behavior classification suitable for outcome stratification? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 The prognostic factor in patients with myositis-associated interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Progressive fibrosis is common in patients with Sjögren’s syndrome and Interstitial lung disease Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Childhood diffuse parenchymal lung diseases: Diagnosis, treatment and outcome Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Recent improvement of survival of acute exacerbation in idiopathic interstitial pneumonias: 10 years experience Source: International Congress 2014 – ILDs 2 Year: 2014 Acute exacerbations of progressive-fibrosing interstitial lung diseases Source: Eur Respir Rev, 27 (150) 180071; 10.1183/16000617.0071-2018 Year: 2018 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014